Strongbridge Biopharma plc Announces $35 Million Equity Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Strongbridge Biopharma (SBBP) Tops Q1 EPS by 12c
December 23, 2016 8:08 AM ESTStrongbridge Biopharma (NASDAQ: SBBP) reported Q1 EPS of ($0.57), $0.12 better than the analyst estimate of ($0.69).
For earnings history and earnings-related data on Strongbridge Biopharma (SBBP) click here.
... MoreStrongbridge Biopharma (SBBP) Acquires U.S. Rights to KEVEYIS
December 23, 2016 8:08 AM ESTStrongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has acquired the U.S. rights to KEVEYIS® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (Taro). KEVEYIS was approved by the U.S. Food and Drug Administration (FDA) in August 2015 to treat hyperkalemic, hypokalemic, and related variants of... More
